Document Detail

Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.
MedLine Citation:
PMID:  12585949     Owner:  NLM     Status:  MEDLINE    
CONTEXT: Beta-blockers remain underused despite their established utility for improving outcome in heart failure. Concerns that initiation of treatment produces few immediate benefits and may have important risks may be deterring widespread use.
OBJECTIVE: To evaluate the early effects of the beta-blocker carvedilol in patients with severe heart failure.
DESIGN, SETTING, AND PATIENTS: Randomized, double-blind, placebo-controlled trial conducted from October 28, 1997, to March 20, 2000, at 334 hospital centers in 21 countries among 2289 patients with symptoms of heart failure at rest or with minimal exertion who were clinically euvolemic and had a left ventricular ejection fraction of less than 25%.
INTERVENTION: Patients were randomly assigned to receive carvedilol, with start dosage of at 3.125 mg twice daily with uptitration to a target dosage of 25 mg twice daily (n = 1156), or placebo (n = 1133), in addition to their usual medications for heart failure.
MAIN OUTCOME MEASURES: Death, hospitalization, or permanent withdrawal from study drug, as well as adverse events during the first 8 weeks of treatment.
RESULTS: The carvedilol group experienced no increase in cardiovascular risk but instead had fewer patients who died (19 vs 25; hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.41-1.35); who died or were hospitalized (134 vs 153; HR, 0.85; 95% CI, 0.67-1.07); or who died, were hospitalized, or were permanently withdrawn from treatment (162 vs 188; HR, 0.83; 95% CI, 0.68-1.03). These effects were similar in direction and magnitude to those observed during the entire study, and were apparent particularly in the 624 patients with recent or recurrent decompensation or a very depressed left ventricular ejection fraction. Differences in favor of carvedilol became apparent as early as 14 to 21 days following initiation of treatment. Worsening heart failure was the only serious adverse event with a frequency greater than 2% and was reported with similar frequency in the placebo and carvedilol groups (6.4% vs 5.1%).
CONCLUSIONS: These data suggest that, in clinically euvolemic patients, the relation of benefit to risk during initiation of treatment with carvedilol is similar to that seen during long-term therapy with the drug. Our findings should provide the reassurance needed to encourage the high levels of use that are warranted by the results of long-term clinical trials.
Henry Krum; Ellen B Roecker; Paul Mohacsi; Jean L Rouleau; Michal Tendera; Andrew J S Coats; Hugo A Katus; Michael B Fowler; Milton Packer;
Related Documents :
3346979 - Primary prevention with metoprolol in patients with hypertension. mortality results fro...
17885779 - Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy seco...
12660669 - Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in...
16337039 - Body composition changes in patients with systolic heart failure treated with beta bloc...
8743519 - Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with micr...
2893529 - International beta-blocker review in acute and postmyocardial infarction.
20221769 - Weight change following deep brain stimulation for movement disorders.
16261429 - Self-expandable metallic stent placement for palliation in gastric outlet obstructions ...
23472309 - Tracheotomy tubes with suction above the cuff reduce the rate of ventilator-associated ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  JAMA     Volume:  289     ISSN:  0098-7484     ISO Abbreviation:  JAMA     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-02-14     Completed Date:  2003-02-25     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  United States    
Other Details:
Languages:  eng     Pagination:  712-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / administration & dosage,  adverse effects,  therapeutic use*
Carbazoles / administration & dosage,  adverse effects,  therapeutic use*
Double-Blind Method
Heart Failure / drug therapy*
Propanolamines / administration & dosage,  adverse effects,  therapeutic use*
Survival Analysis
Treatment Outcome
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Carbazoles; 0/Propanolamines; 0K47UL67F2/carvedilol
Comment In:
JAMA. 2003 Feb 12;289(6):754-6   [PMID:  12585956 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Change in cognitive function over time in very low-birth-weight infants.
Next Document:  Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult ...